Alnylam Pharmaceuticals Inc 2025 Sustainability Report
Company: Alnylam Pharmaceuticals Inc
Sector: Manufacturing
Country: United States
Year: 2025
Type: Sustainability Report
Pages: 117
The report describes a defining 2025 for Alnylam, including the launch of AMVUTTRA® for ATTR cardiomyopathy and the completion of its P5x25 strategy. It also details a new double materiality assessment and expanded Corporate Responsibility governance across patients, science, employees, communities, environment, and integrity. The company reports 2,502 employees globally and continued progress on inclusion and employee engagement. Environmental disclosures include 2025 Scope 1, Scope 2, Scope 3, energy, water, and waste data, with the GHG inventory independently verified at a limited assurance level.
Reporting standards, commitments and assurance details are available with a free account.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.